Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Background The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214
booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …

SARS-CoV-2 in an Immunocompromised Host This letter describes an immunocompromised
patient who had persistent infection with SARS-CoV-2 over a period of months, despite …

Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …

Omicron Neutralization and mRNA-1273 Boosters Neutralization of the omicron variant was
assessed in serum samples obtained from persons who had received an mRNA-1273 …

Background Patients with persistent fever and neutropenia often receive empirical therapy
with conventional or liposomal amphotericin B for the prevention and early treatment of …

Objective To provide guidance to rheumatology providers on the use of coronavirus disease
2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases (…

Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …

Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs)
on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …